CytomX Therapeutics Inc. (CTMX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CytomX Therapeutics Inc. (CTMX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.85

-0.04 (-4.21%)

At close: Jan 14, 2025, 3:59 PM

0.87

2.09%

After-hours Jan 14, 2025, 06:04 PM EST

undefined% (undefined)

Bid	0.92
Market Cap	66.53M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.16
PE Ratio (ttm)	5.31
Forward PE	n/a
Analyst	Hold

Ask	0.95
Volume	1,055,966
Avg. Volume (20D)	1,278,563
Open	0.89
Previous Close	0.89
Day's Range	0.81 - 0.92
52-Week Range	0.81 - 5.85
Beta	undefined

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 8, 2015

Employees 120

Stock Exchange NASDAQ

Ticker Symbol CTMX

Website https://www.cytomx.com

Analyst Forecast

According to 6 analyst ratings, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $5.79, which is an increase of 581.10% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

CytomX Therapeutics Inc. is scheduled to release its earnings on Mar 10, 2025, during market hours.
Analysts project revenue of $13.53M, reflecting a -49.15% YoY shrinking and earnings per share of -0.13, making a -1400.00% decrease YoY.

Why Price Moved

2 months ago · Source

+9%

CytomX Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

8 months ago · Source

-51.31%

CytomX Therapeutics shares are trading lower, pulling back after surging after hours Thursday following initial data from the ongoing CX-904 Phase 1a dose escalation clinical study.

News

1 week ago · zacks.com

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

4 weeks ago · zacks.com

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

1 month ago · zacks.com

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

2 months ago · seekingalpha.com

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Partici...

2 months ago · zacks.com

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year a...